A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the intratumoral administration of escalating doses of a novel,
experimental drug, INT230-6. The study is being conducted in patients with several types of
refractory cancers including those at the surface of the skin (breast, squamous cell, head
and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor
also plans to test INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Intensity Therapeutics, Inc.
Collaborators:
Bristol-Myers Squibb Merck Sharp & Dohme Corp. University Health Network, Toronto University of Southern California